ES2617200T3 - Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7 - Google Patents

Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7 Download PDF

Info

Publication number
ES2617200T3
ES2617200T3 ES12759150.1T ES12759150T ES2617200T3 ES 2617200 T3 ES2617200 T3 ES 2617200T3 ES 12759150 T ES12759150 T ES 12759150T ES 2617200 T3 ES2617200 T3 ES 2617200T3
Authority
ES
Spain
Prior art keywords
lymphocytes
ccr9
foxp3
directed against
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12759150.1T
Other languages
English (en)
Spanish (es)
Inventor
Giovanni Monteleone
Francesca Viti
Salvatore Bellinvia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Application granted granted Critical
Publication of ES2617200T3 publication Critical patent/ES2617200T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES12759150.1T 2011-09-15 2012-09-14 Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7 Active ES2617200T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11425234 2011-09-15
EP11425234 2011-09-15
US201161576556P 2011-12-16 2011-12-16
US201161576556P 2011-12-16
PCT/EP2012/068146 WO2013037970A1 (en) 2011-09-15 2012-09-14 Methods for monitoring responsiveness to anti-smad7 therapy

Publications (1)

Publication Number Publication Date
ES2617200T3 true ES2617200T3 (es) 2017-06-15

Family

ID=47882658

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12759150.1T Active ES2617200T3 (es) 2011-09-15 2012-09-14 Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7

Country Status (11)

Country Link
US (2) US9791442B2 (enExample)
EP (2) EP3165929A3 (enExample)
JP (1) JP6389122B2 (enExample)
KR (1) KR102099990B1 (enExample)
CN (1) CN104040349B (enExample)
AU (1) AU2012307336B2 (enExample)
CA (1) CA2848595A1 (enExample)
ES (1) ES2617200T3 (enExample)
MX (1) MX350087B (enExample)
RU (1) RU2678450C2 (enExample)
WO (1) WO2013037970A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
EP2970419B8 (en) * 2013-03-15 2019-12-11 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
US20160139123A1 (en) * 2013-07-12 2016-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Shear Wave Imaging Method and Installation for Collecting Information on a Soft Solid
RU2016147569A (ru) * 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
US10337004B2 (en) * 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
EP3213070A2 (en) * 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
WO2017019673A2 (en) * 2015-07-27 2017-02-02 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
WO2017055611A2 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
US20180289692A1 (en) * 2015-09-30 2018-10-11 Celgene Corporation Tlr modulators and methods of use
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
US11619832B2 (en) 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
CN110082538B (zh) * 2019-04-19 2021-12-03 中山大学附属第六医院 CCR9+IL-17+Treg细胞在制备用于检测NEC的试剂盒中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
RU2185627C2 (ru) * 2000-09-11 2002-07-20 Новосибирская государственная медицинская академия Способ определения чувствительности (восприимчивости) к внутривенной лазеротерапии больных ишемической болезнью сердца
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
WO2007014420A1 (en) 2005-08-02 2007-02-08 Centenary Institute Of Cancer Medicine And Cell Biology Method for identifying regulatory t cells
AU2007224967A1 (en) * 2006-03-10 2007-09-20 Mount Sinai Hospital Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover
JP2010531138A (ja) * 2007-06-13 2010-09-24 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 制御性ｔ細胞ならびに同製造および使用方法
JPWO2009107785A1 (ja) * 2008-02-28 2011-07-07 シスメックス株式会社 Ｉｌ−１７産生ヘルパーｔ細胞検出用マーカー及びｉｌ−１７産生ヘルパーｔ細胞の検出方法
JP2010051307A (ja) 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
EP2452194B1 (en) 2009-07-10 2015-11-11 Transgene SA Biomarker for selecting patients and related methods
US8766034B2 (en) * 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
EP2970419B8 (en) 2013-03-15 2019-12-11 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2016147569A (ru) 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
WO2017055611A2 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Also Published As

Publication number Publication date
CN104040349B (zh) 2017-07-04
AU2012307336A1 (en) 2014-03-27
RU2678450C2 (ru) 2019-01-29
EP3165929A3 (en) 2017-06-21
KR20140059859A (ko) 2014-05-16
EP2748611B1 (en) 2016-11-23
NZ719884A (en) 2020-02-28
WO2013037970A1 (en) 2013-03-21
NZ622067A (en) 2016-05-27
CN104040349A (zh) 2014-09-10
EP2748611A1 (en) 2014-07-02
CA2848595A1 (en) 2013-03-21
AU2012307336B2 (en) 2017-08-24
EP3165929A2 (en) 2017-05-10
JP2014531584A (ja) 2014-11-27
RU2014114838A (ru) 2015-10-20
KR102099990B1 (ko) 2020-04-13
US20180128829A1 (en) 2018-05-10
MX350087B (es) 2017-08-24
US20150148245A1 (en) 2015-05-28
JP6389122B2 (ja) 2018-09-12
MX2014003295A (es) 2014-05-28
HK1199095A1 (en) 2015-06-19
US9791442B2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
AU2012307336B2 (en) Methods for monitoring responsiveness to anti-SMAD7 therapy
Huang et al. SARS-CoV-2 infection of the oral cavity and saliva
Hollerbach et al. Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19
US20230051905A1 (en) Triaging method using cell free nucleosome levels
US20220187313A1 (en) Diagnosis or Prognosis of Postsurgical Adverse Events
CA3000569A1 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
CN109069513B (zh) 用于治疗或预防肝癌的组合物
WO2018025923A1 (ja) 抗ｈｔｌｖ－１剤、ｈｔｌｖ－１関連脊髄症（ｈａｍ／ｔｓｐ）治療薬
Chauhan et al. Differential clearance mechanisms, neutrophil extracellular trap degradation and phagocytosis, are operative in systemic lupus erythematosus patients with distinct autoantibody specificities
Wöhler et al. Monocyte derived large extracellular vesicles in polytrauma
EP3922641A1 (en) Methods for detecting and treating covid patients requiring intensive care
Giordani et al. Increased frequency of immunoglobulin (Ig) A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease
Li et al. NETs promote fibroblast-like synoviocytes producing IL-6 to enhance T follicular helper cell response in rheumatoid arthritis
Hruskova et al. Intracellular cytokine production in ANCA-associated vasculitis: low levels of interleukin-10 in remission are associated with a higher relapse rate in the long-term follow-up
Runge et al. Viral infection in chronic otitis media with effusion in children
CN113533737A (zh) Nfam1在筛选防治冠心病药物或制备试剂盒中的应用
Barbon et al. Innate immune response in COVID-19: single-cell multi-omics profile of NK lymphocytes in a clinical case series
US20200237801A1 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
Li et al. Increased expression of long-isoform thymic stromal lymphopoietin is associated with rheumatoid arthritis and fosters inflammatory responses
RU2790962C1 (ru) Способ прогнозирования тяжелого течения геморрагической лихорадки с почечным синдромом на ранних этапах заболевания
Doğan et al. IL‐36 signaling pathway dysregulation in Crimean–Congo hemorrhagic fever virus patients: A potential therapeutic avenue
HK1199095B (en) Methods for monitoring responsiveness to anti-smad7 therapy
NZ719884B2 (en) Methods for monitoring responsiveness to anti-SMAD7 therapy
NZ622067B2 (en) Methods for monitoring responsiveness to anti-smad7 therapy
Duizendstra Rejection and Tolerance after Liver Transplantation